Vaxart, Inc. Form 8-K (Nov. 16, 2020)

Summary

Form 8-K for an event dated November 16, 2020, filed by Vaxart, Inc. Under Item 1.01, Entry into a Material Definitive Agreement, the report states that on November 16, 2020 the company and Vera Therapeutics, Inc. entered into a sublease of approximately 24,606 rentable square feet of office and research laboratory space on the third floor of a building in South San Francisco, California. The term runs from December 1, 2020 to September 30, 2025. Rent is $95,963.40 per month, rising by three and one-half percent annually, with a pass-through of building real estate taxes and expenses. The master landlord is Britannia Pointe Grand Limited Partnership. Andrei Floroiu, President and Chief Executive Officer, signed November 19, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

vxrt20201118b_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1 6 , 2020

Vaxart, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-35285 | 59-1212264
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
385 Oyster Point Boulevard, Suite 9A, South San Francisco, California | 94080
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (650) 550-3500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading symbol | Name of each exchange on which registered
Common stock, $0.0001 par value | VXRT | The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On November 16, 2020, Vaxart, Inc. (the “ Company ” ) and Vera Therapeutics, Inc. (“ Vera ”) entered into a sublease (the “ Sublease ”) of approximately 24,606 rentable square feet of office and research laboratory space located on the third (3rd) floor of a building located at 170 Harbor Way, South San Francisco, California for a term commencing on December 1, 2020 and terminating on September 30, 2025. The space is currently leased by Vera and the master landlord is Britannia Pointe Grand Limited Partnership. The rent payable under the Sublease is $95,963.40 per month, which amount shall increase by three and one-half percent (3.5%) annually. The Sublease provides for a pass-through of building real estate taxes and expenses.

A copy of the Sublease will be filed as an exhibit to the Company’s next periodic report, and the description of the Sublease is qualified in its entirety by reference to such exhibit.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Vaxart, Inc.
Dated: November 19, 2020
By: | /s/ Andrei Floroiu
Andrei Floroiu
President and Chief Executive Officer

File and source

File

SEC_VXRT_8-K_filed2020-11-19_0001437749-20-024248.htm

Size

30,768 bytes

SHA-256

d214a453754429043bb60de5155dcf82ef16d697dec43a7a14eb6d53a3e7623e

Our copy

SEC_VXRT_8-K_filed2020-11-19_0001437749-20-024248.htm

Original

www.sec.gov